Across TCGA pan-cancer cohorts, LINC01856 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated LINC01856 data layer compared with 12 for mass-spec protein.
The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher LINC01856 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated LINC01856 expression acts as an unfavorable survival marker.
LUSC are the cancer types where LINC01856 Mutation most reproducibly stratifies survival.